An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL

NCT06015464 · clinicaltrials.gov ↗

UNKNOWN

Status

81

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type

Interventions

DRUG: Orelabrutinib

Sponsor

The First Affiliated Hospital with Nanjing Medical University